vTv Therapeutics Q3 net loss widens to $4.3M; appoints new CEO, plans Phase 3 for TTP399

vTv Therapeutics Inc.

Net loss of $4.3M ($0.05/share) vs. $1.1M loss a year ago, driven by higher R&D and G&A costs.
Appointed Paul Sekhri as President & CEO effective August 1, 2022, succeeding prior leadership.
CinRx Pharma subsidiary to invest $10M in common stock and provide collaboration for TTP399 trials.
Cash position $15.3M as of Sept 30, 2022, up from $13.4M at year-end 2021.
Company plans two pivotal Phase 3 trials of TTP399 for type 1 diabetes starting Q1 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

vTv Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income $4.3 million or $0.05 per basic share, EPS $0.05 per basic share.

Period: the third quarter ended September 30, 2022
Net income: $4.3 million or $0.05 per basic share
EPS: $0.05 per basic share
Result: reported results

Exact text from the filing

Net loss attributable to vTv shareholders for the three months ended September 30, 2022, was $4.3 million or $0.05 per basic share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-22-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.